Hutch News

Hutch News

Stories tagged 'clinical trials'

HIV prevention gains bring hope — and challenges

Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated

Oct. 14, 2016 | By Mary Engel / Fred Hutch News Service

An injectable form of PrEP and other options are in the pipeline as the HIV field enters a new era of prevention. But such advances, as welcome as they are, come with a twist: They complicate the task of designing the clinical trials needed to test additional tools. Fred Hutch's Dr. Deborah Donnell explains.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Oct. 13, 2016

Dr. David Maloney named cellular immunotherapy medical director at Fred Hutch, SCCA; Dr. Jim Kublin gets grant to study how gut bugs alter HIV vaccine response.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 22, 2016

Dr. Candice Grzelak gets $180K to study breast cancer mets; Infectious Disease Sciences earns training grant; Drs. Jesse Bloom, Frederick "Erick" Matsen named HHMI-Simons Faculty Scholars

View story >

'Every basic scientist's dream'

How Dr. Barry Stoddard's lab work helped create an experimental drug for glioblastoma — the same disease that killed his mother

July 27, 2016 | By Rachel Tompa / Fred Hutch News Service

Dr. Barry Stoddard's research to modify a protein from yeast is now helping to fuel a promising therapy for glioblastoma — the disease that killed his mother.

View story >

Getting malaria on purpose

Volunteers roll up their sleeves and get infected to test an experimental drug

April 25, 2016 | By Mary Engel / Fred Hutch News Service

Eight healthy adults ranging in age from 20 to 37 are taking part in a new study conducted by the Seattle Malaria Clinical Trials Center, run by Fred Hutchinson Cancer Research Center and the Center for Infectious Disease Research.

View story >

'Finally showing hope'

Immunotherapy trial results transforming care for rare skin cancer

April 19, 2016 | By Susan Keown / Fred Hutch News Service

With few remaining options for treating his aggressive Merkel cell carcinoma, Stan Collender joined a clinical trial of the immune-modulating drug pembrolizumab. The trial's results are giving new hope to people with this rare cancer.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.